ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,722,151 | -48.6% | 959,906 | -1.5% | 0.00% | -50.0% |
| Q2 2023 | $20,860,228 | -40.2% | 974,777 | +12.9% | 0.00% | -42.9% |
| Q1 2023 | $34,912,499 | -15.0% | 863,316 | -2.2% | 0.01% | -22.2% |
| Q4 2022 | $41,083,208 | -17.9% | 883,130 | -8.4% | 0.01% | -18.2% |
| Q3 2022 | $50,023,000 | +13.6% | 964,407 | +3.6% | 0.01% | +22.2% |
| Q2 2022 | $44,022,000 | -33.4% | 931,291 | +0.3% | 0.01% | -25.0% |
| Q1 2022 | $66,061,000 | -12.7% | 928,093 | -8.3% | 0.01% | 0.0% |
| Q4 2021 | $75,689,000 | +38.9% | 1,012,164 | +5.5% | 0.01% | +20.0% |
| Q3 2021 | $54,483,000 | +90.8% | 959,048 | +47.8% | 0.01% | +100.0% |
| Q2 2021 | $28,554,000 | -10.2% | 648,802 | +0.6% | 0.01% | -16.7% |
| Q1 2021 | $31,807,000 | +217.8% | 644,914 | +171.3% | 0.01% | +200.0% |
| Q4 2020 | $10,009,000 | -11.9% | 237,729 | -4.2% | 0.00% | 0.0% |
| Q3 2020 | $11,355,000 | -11.2% | 248,041 | -2.6% | 0.00% | -33.3% |
| Q2 2020 | $12,787,000 | -3.8% | 254,660 | -1.5% | 0.00% | -25.0% |
| Q1 2020 | $13,298,000 | -8.1% | 258,566 | +10.4% | 0.00% | +33.3% |
| Q4 2019 | $14,476,000 | -0.3% | 234,298 | -3.0% | 0.00% | 0.0% |
| Q3 2019 | $14,518,000 | -26.5% | 241,647 | +3.3% | 0.00% | -40.0% |
| Q2 2019 | $19,749,000 | -10.6% | 234,037 | +1.1% | 0.01% | 0.0% |
| Q1 2019 | $22,101,000 | +29.6% | 231,380 | -3.9% | 0.01% | 0.0% |
| Q4 2018 | $17,055,000 | -13.8% | 240,803 | +4.0% | 0.01% | 0.0% |
| Q3 2018 | $19,792,000 | -23.7% | 231,596 | +3.4% | 0.01% | -28.6% |
| Q2 2018 | $25,955,000 | +67.2% | 223,943 | +16.7% | 0.01% | +75.0% |
| Q1 2018 | $15,521,000 | +32.0% | 191,830 | -4.3% | 0.00% | +33.3% |
| Q4 2017 | $11,757,000 | +28.5% | 200,357 | +2.5% | 0.00% | +50.0% |
| Q3 2017 | $9,151,000 | +30.0% | 195,523 | -0.1% | 0.00% | 0.0% |
| Q2 2017 | $7,041,000 | +21.6% | 195,712 | +4.1% | 0.00% | 0.0% |
| Q1 2017 | $5,789,000 | -9.2% | 187,940 | -1.2% | 0.00% | 0.0% |
| Q4 2016 | $6,375,000 | +31.1% | 190,311 | +4.1% | 0.00% | 0.0% |
| Q3 2016 | $4,864,000 | +24.6% | 182,817 | +3.3% | 0.00% | +100.0% |
| Q2 2016 | $3,904,000 | -28.7% | 177,047 | -5.0% | 0.00% | -50.0% |
| Q1 2016 | $5,475,000 | -8.5% | 186,373 | +2.8% | 0.00% | 0.0% |
| Q4 2015 | $5,985,000 | -6.5% | 181,269 | +2.3% | 0.00% | 0.0% |
| Q3 2015 | $6,402,000 | +9.4% | 177,159 | +36.2% | 0.00% | 0.0% |
| Q2 2015 | $5,850,000 | +58.3% | 130,039 | +7.8% | 0.00% | +100.0% |
| Q1 2015 | $3,696,000 | -39.7% | 120,676 | +0.1% | 0.00% | -50.0% |
| Q4 2014 | $6,129,000 | +27.7% | 120,533 | -0.7% | 0.00% | 0.0% |
| Q3 2014 | $4,800,000 | +97.4% | 121,322 | +114.9% | 0.00% | +100.0% |
| Q2 2014 | $2,431,000 | +18.6% | 56,443 | +10.2% | 0.00% | 0.0% |
| Q1 2014 | $2,049,000 | +40.3% | 51,239 | -4.2% | 0.00% | – |
| Q4 2013 | $1,460,000 | +28.6% | 53,513 | +8.0% | 0.00% | – |
| Q3 2013 | $1,135,000 | +378.9% | 49,536 | +269.7% | 0.00% | – |
| Q2 2013 | $237,000 | – | 13,398 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |